Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Mov Disord ; 29(3): 344-50, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24436111

ABSTRACT

Rapid-onset dystonia-parkinsonism (RDP) is caused by mutations in the ATP1A3 gene. This observational study sought to determine if cognitive performance is decreased in patients with RDP compared with mutation-negative controls. We studied 22 familial RDP patients, 3 non-motor-manifesting mutation-positive family members, 29 mutation-negative family member controls in 9 families, and 4 unrelated RDP patients, totaling 58 individuals. We administered a movement disorder assessment, including the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) and the Unified Parkinson's Disease Rating Scale (UPDRS) and a cognitive battery of memory and learning, psychomotor speed, attention, and executive function. The cognitive battery was designed to evaluate a wide range of functions; recognition memory instruments were selected to be relatively pure measures of delayed memory, devoid of significant motor or vocal production limitations. Comparisons of standardized cognitive scores were assessed both with and without controlling for psychomotor speed and similarly for severity of depressive symptoms. A majority of RDP patients had onset of motor symptoms by age 25 and had initial symptom presentation in the upper body (face, mouth, or arm). Among patients, the BFMDRS (mean ± SD, 52.1 ± 29.5) and UPDRS motor subscore (29.8 ± 12.7) confirmed dystonia-parkinsonism. The affected RDP patients performed more poorly, on average, than mutation-negative controls for all memory and learning, psychomotor speed, attention, and executive function scores (all P ≤ 0.01). These differences persisted after controlling for psychomotor speed and severity of depressive symptoms. Impaired cognitive function may be a manifestation of ATP1A3 mutation and RDP.


Subject(s)
Cognition Disorders/genetics , Dystonia/genetics , Parkinsonian Disorders/genetics , Sodium-Potassium-Exchanging ATPase/genetics , Adult , Age of Onset , Aged , Cognition Disorders/complications , Female , Genetic Predisposition to Disease , Humans , Male , Middle Aged , Movement Disorders/genetics , Mutation/genetics , Parkinsonian Disorders/complications
2.
Neurology ; 79(11): 1168-73, 2012 Sep 11.
Article in English | MEDLINE | ID: mdl-22933743

ABSTRACT

OBJECTIVE: Rapid-onset dystonia-parkinsonism (RDP) is caused by a variety of missense mutations in the ATP1A3 gene. Psychiatric comorbidity has been reported, although systematic examination of psychiatric disease in individuals with RDP is lacking. This study examines psychiatric morbidity for 23 patients with RDP in 10 families with family member control subjects and in 3 unrelated patients with RDP, totaling 56 individuals. METHODS: Twenty-nine ATP1A3 mutation-positive individuals were examined; 26 exhibited motor symptoms (motor manifesting carrier [MMC]) and 3 did not (nonmotor manifesting carriers [NMC]). Twenty-seven ATP1A3 mutation-negative participants (noncarriers [NC]) were included. Rates of psychiatric illness for patients with RDP and related asymptomatic gene mutation carriers were compared with those for related nonmutation carriers. Outcome measures included the Unified Parkinson's Disease Rating Scale, Burke-Fahn-Marsden Dystonia Rating Scale, Instrumental Activities of Daily Living, Composite International Diagnostic Interview, Structured Clinical Interview for DSM-IV, Hamilton Depression Scale, Hamilton Anxiety Scale, and Yale-Brown Obsessive-Compulsive Scale. RESULTS: NMC participants did not report any history of psychiatric disorder. Findings in MMC and NC groups included anxiety (MMC 48, NC 41%), mood (MMC 50%, NC 22%), psychotic (MMC 19%, NC 0%), and substance abuse/dependence (MMC 38%, NC 27%). CONCLUSIONS: ATP1A3 mutations cause a wide spectrum of motor and nonmotor features. Psychotic symptoms tended to emerge before or concurrent with motor symptom onset, suggesting that this could be another expression of the ATP1A3 gene mutation.


Subject(s)
Dystonic Disorders/complications , Mental Disorders/complications , Activities of Daily Living , Adolescent , Adult , Aged , Aged, 80 and over , Dystonic Disorders/genetics , Dystonic Disorders/psychology , Female , Heterozygote , Humans , Male , Mental Disorders/diagnosis , Mental Disorders/genetics , Middle Aged , Psychiatric Status Rating Scales , Sodium-Potassium-Exchanging ATPase/genetics
3.
Dev Med Child Neurol ; 54(11): 1065-7, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22924536

ABSTRACT

We report new clinical features of delayed motor development, hypotonia, and ataxia in two young children with mutations (R756H and D923N) in the ATP1A3 gene. In adults, mutations in ATP1A3 cause rapid-onset dystonia-Parkinsonism (RDP, DYT12) with abrupt onset of fixed dystonia. The parents and children were examined and videotaped, and samples were collected for mutation analysis. Case 1 presented with fluctuating spells of hypotonia, dysphagia, mutism, dystonia, and ataxia at 9 months. After three episodes of hypotonia, she developed ataxia, inability to speak or swallow, and eventual seizures. Case 2 presented with hypotonia at 14 months and pre-existing motor delay. At age 4 years, he had episodic slurred speech, followed by ataxia, drooling, and dysarthria. He remains mute. Both children had ATP1A3 gene mutations. To our knowledge, these are the earliest presentations of RDP, both with fluctuating features. Both children were initially misdiagnosed. RDP should be considered in children with discoordinated gait, and speech and swallowing difficulties.


Subject(s)
Dystonic Disorders/genetics , Mutation/genetics , Phenotype , Sodium-Potassium-Exchanging ATPase/genetics , Adult , Ataxia/etiology , Ataxia/genetics , Developmental Disabilities/etiology , Developmental Disabilities/genetics , Dystonic Disorders/complications , Dystonic Disorders/diagnosis , Female , Humans , Infant , Male , Middle Aged
4.
Parkinsonism Relat Disord ; 18(6): 737-41, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22534615

ABSTRACT

BACKGROUND: A woman from Italy presented with dystonic leg symptoms at the age of 59. Rapid-onset dystonia-parkinsonism (RDP) was not suspected until 3 affected children (2 male, 1 female) with presentations consistent with the disorder were recognized. METHODS: The mother and four of her children (3 with and 1 without dystonia) were evaluated with an extensive battery including standardized history questionnaire and rating scales. In addition, all four children had cognitive testing and three of the four children had psychiatric interviews. RESULTS: In this family, a T613M mutation in the ATP1A3 gene was confirmed, the most common mutation present in patients with RDP. The proband's limb dystonia was atypical of RDP, symptoms of the others affected included dysarthria, asymmetric limb dystonia, and dysphagia more consistent with RDP. The two sons developed dystonia-parkinsonism in adolescence after consuming large amounts of alcohol. All 3 of those with psychiatric interviews reached diagnosable thresholds for mood disorder (bipolar or dysthymia) and some form of anxiety disorder. CONCLUSIONS: The phenotype and age of onset is broader than previously reported in RDP, suggesting that it could be under-reported. Prior to this study, neuropsychologic symptoms associated with RDP were under-appreciated. Those patients who are at risk or suspected of having RDP should be cautioned to avoid excessive alcohol intake. Further study is needed to assess if the cognitive and psychiatric features are part of a broader RDP phenotype and this may have implications for future research into genetic susceptibility for psychiatric disease.


Subject(s)
Alcoholism/complications , Anxiety Disorders/complications , Dystonic Disorders/complications , Dystonic Disorders/genetics , Mood Disorders/complications , Sodium-Potassium-Exchanging ATPase/genetics , Adult , Alcohol Drinking , Female , Genetic Predisposition to Disease , Genotype , Hot Temperature , Humans , Male , Middle Aged , Neuropsychological Tests , Pedigree , Phenotype , Polymorphism, Single Nucleotide , Precipitating Factors
5.
Appl Ergon ; 43(2): 386-91, 2012 Mar.
Article in English | MEDLINE | ID: mdl-21718964

ABSTRACT

Six married couples (12 adults, mean age 34.8 years) were randomized as couples in a cross-over design to sleep on a queen-size conventional mattress for 2 weeks and a specially-designed pressure-relief mattress for 2 weeks. The pressure-relief mattress was designed to reduce the number of contact points exceeding 30 mm Hg. Actigraphic measurements of sleep and self-reports of sleep and daytime symptoms were collected at baseline for 2 weeks on each couple's home mattress and box springs at home, followed by 2 weeks of data collection on each randomized mattress for a total of 6 weeks of data collection. Pressure maps were created for each participant on each sleeping surface. There were no significant differences between the randomized sleeping surfaces for any measure of actigraphic sleep or self-reported sleep and daytime symptoms. However, poor pressure relief performance of the home mattress was associated with better actigraphic sleep on the randomized pressure-relief mattress. We conclude that while pressure-relief mattresses may not be universally preferred, baseline characteristics of the sleeper and/or their mattress may explain performance and sleeper preferences on future mattress selection.


Subject(s)
Beds , Sleep/physiology , Actigraphy , Adult , Cross-Over Studies , Equipment Design , Female , Humans , Male , Middle Aged , Pilot Projects , Pressure
6.
Sleep Med ; 12(6): 557-64, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21601519

ABSTRACT

OBJECTIVES: Our prior work has shown that there is improvement in self-reported sleep in persons receiving placebo in hypnotic clinical trials. We examined the components of the "placebo response" in a hypnotic clinical trial. METHODS: This was an exploratory analysis of a randomized, double-blind clinical trial of eszopiclone versus placebo in the treatment of persons with depression and insomnia who were also receiving fluoxetine at a clinic of a teaching hospital. Sixty adults with both depression and insomnia symptoms, who were free of significant primary sleep disorders, received open-label fluoxetine for 9weeks. Patients were further randomized 1:1 to receive either masked eszopiclone 3mg or placebo at bedtime after the first week of fluoxetine. We examined the respective contributions of three factors associated with the "placebo effect": (1) regression to the mean, (2) expectancy, and (3) social desirability. RESULTS: There was evidence for regression to the mean for the continuous measurement of the Insomnia Severity Index (ISI) and the Hamilton Depression Rating Scale. There was evidence for expectancy in self-reported Wake After Sleep Onset, continuous measurement of ISI, and dichotomous remission/non-remitter measurement of ISI. There was evidence of social desirability affecting self-reported Total Sleep Time. CONCLUSIONS: Factors that have been associated with the "placebo effect" are operating in hypnotic clinical trials. However, the role of each factor differs depending upon which self-reported variable is being considered. The findings have implications for clinical trial design in insomnia.


Subject(s)
Azabicyclo Compounds/therapeutic use , Depressive Disorder/drug therapy , Hypnotics and Sedatives/therapeutic use , Piperazines/therapeutic use , Sleep Initiation and Maintenance Disorders/drug therapy , Adult , Antidepressive Agents, Second-Generation/therapeutic use , Drug Therapy, Combination , Eszopiclone , Female , Fluoxetine/therapeutic use , Humans , Male , Middle Aged , Placebo Effect , Psychiatric Status Rating Scales , Severity of Illness Index , Sleep/drug effects , Sleep/physiology , Wakefulness/drug effects , Wakefulness/physiology
7.
J Clin Sleep Med ; 6(4): 322-9, 2010 Aug 15.
Article in English | MEDLINE | ID: mdl-20726279

ABSTRACT

STUDY OBJECTIVES: Insomnia is associated with poor health related quality of life (HRQOL) in depressed patients. Prior clinical trials of hypnotic treatment of insomnia in depressed patients have shown improvement in HRQOL, but in these studies HRQOL was relegated to a secondary outcome, and objective measures of sleep were not undertaken. DESIGN: Double-blind, randomized, placebo-controlled clinical trial. SETTING: Outpatient clinic and sleep laboratory. PATIENTS: 60 depressed, insomniac outpatients. INTERVENTIONS: One week of open-label fluoxetine (FLX), followed by 8 more weeks of FLX combined with either eszopiclone (ESZ) 3 mg or placebo at bedtime. MEASUREMENTS: The primary HRQOL measure was the daily living and role functioning subscale (DLRF) of the Basis-32. Other measures included the Q-LES-Q, self-reported sleep, PSG, actigraphy, depression severity (HRSD). RESULTS: At the end of randomized treatment, patients receiving ESZ had lower (better) DLRF scores (0.81 +/- 0.64) than those receiving placebo (1.2 +/- 0.72), p = 0.01. The effect size for DLRF was 0.62, indicating a moderate effect. An advantage for ESZ was also seen in other measures of HRQOL, and most assessments of antidepressant efficacy and sleep. Women reported better end of treatment HRQOL scores than men. CONCLUSIONS: ESZ treatment of insomnia in depressed patients is associated with multiple favorable outcomes, including superior improvement in HRQOL, depression severity, and sleep.


Subject(s)
Antidepressive Agents, Second-Generation/therapeutic use , Azabicyclo Compounds/therapeutic use , Depressive Disorder, Major/drug therapy , Depressive Disorder, Major/psychology , Fluoxetine/therapeutic use , Hypnotics and Sedatives/therapeutic use , Piperazines/therapeutic use , Quality of Life/psychology , Sleep Initiation and Maintenance Disorders/drug therapy , Sleep Initiation and Maintenance Disorders/psychology , Activities of Daily Living/psychology , Affect/drug effects , Antidepressive Agents, Second-Generation/adverse effects , Azabicyclo Compounds/adverse effects , Double-Blind Method , Drug Administration Schedule , Drug Therapy, Combination , Eszopiclone , Female , Fluoxetine/adverse effects , Humans , Hypnotics and Sedatives/adverse effects , Male , Patient Satisfaction , Personality Inventory , Piperazines/adverse effects , Sleep/drug effects , Treatment Outcome
8.
Sleep Med ; 11(9): 822-7, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20478741

ABSTRACT

OBJECTIVE: Insomnia has been linked to suicidal ideas and suicide death in cross-sectional and longitudinal population-based studies. A link between insomnia and suicide has not been previously examined in the setting of a clinical trial. Herein we describe the relationship between insomnia and suicidal thinking during the course of a clinical trial for depression with insomnia. METHODS: Sixty patients aged 41.5±12.5 years (2/3 women) with major depressive episode and symptoms of insomnia received open-label fluoxetine for 9 weeks and also received blinded, randomized eszopiclone 3mg or placebo at bedtime after the first week of fluoxetine. Insomnia symptoms were assessed with the Insomnia Severity Index (ISI), and suicidal ideation was assessed with The Scale for Suicide Ideation (SSI). Depression symptoms were assessed with the depressed mood item and the anhedonia item from the Hamilton Rating Scale for Depression-24 (HRSD24), as well as a sum score for all non-sleep and non-suicide items from the HRSD (HRSD20). Measurements were taken at baseline and weeks 1, 2, 4, 6, and 8. SSI was examined by generalized linear mixed models for repeated measures as the outcome of interest for all 60 participants with ISI and various mood symptoms as independent variables, with adjustment for age, gender, treatment assignment, and baseline SSI. RESULTS: Higher levels of insomnia corresponded to significantly greater intensity of suicidal thinking (p<0.01). The depressed mood item of the HRSD, and the sum of the HRSD20, both corresponded to greater suicidal thinking (p<0.001). The anhedonia item did not correspond with suicidal thinking. When both ISI and the depressed mood item, or ISI and the anhedonia item, were included together in the same model, the ISI remained an independent predictor of suicidal thinking. CONCLUSIONS: The results support the concept that insomnia may be a useful indicator for suicidal ideation and now extend this idea into clinical trials. Insomnia remains an independent indicator of suicidal ideation, even taking into account the core symptoms of depression such as depressed mood and anhedonia. The complaint of insomnia during a depression clinical trial might indicate that more direct questioning about suicide is warranted.


Subject(s)
Depressive Disorder, Major/complications , Sleep Initiation and Maintenance Disorders/psychology , Suicidal Ideation , Adolescent , Adult , Aged , Antidepressive Agents, Second-Generation/therapeutic use , Azabicyclo Compounds/therapeutic use , Depressive Disorder, Major/drug therapy , Depressive Disorder, Major/psychology , Double-Blind Method , Eszopiclone , Female , Fluoxetine/therapeutic use , Humans , Hypnotics and Sedatives/therapeutic use , Male , Middle Aged , Piperazines/therapeutic use , Psychiatric Status Rating Scales , Severity of Illness Index , Sleep Initiation and Maintenance Disorders/complications , Sleep Initiation and Maintenance Disorders/drug therapy , Young Adult
9.
J Clin Sleep Med ; 5(5): 454-8, 2009 Oct 15.
Article in English | MEDLINE | ID: mdl-19961031

ABSTRACT

Insomnia-pharmacology clinical trials routinely exclude primary sleep disorders, such as obstructive sleep apnea (OSA) and periodic limb movement disorder (PLMD), with a single night of polysomnography (PSG). Given the expense of PSG, we examined whether a thorough clinical screening, combined with actigraphy, would successfully identify OSA and PLMD as part of baseline screening for a clinical trial of insomnia treatment in depressed patients. Of the 73 patients with a complete baseline dataset, 12 screened positive for OSA/PLMD (AHI > 15, or PLMAI > 15), while 61 "passed" the PSG screen. The OSA/PLMD+ patients were older (51.4 +/- 10.2 y) and took more naps (2.6 per week) than the OSA/PLMD- patients (41.3 +/- 12.8 y; and 1.1 naps per week). The combination of age and nap frequency produced a "good" receiver operating characteristic (ROC) model for predicting OSA/PLMD+, with the area under the curve of 0.82. There were no other demographic, sleep diary, or actigraphic variables, which differed between OSA/PLM + or -, and no other variable improved the ROC model. Still, the best model misclassified 16 of 73 persons. We conclude that while age and the presence of napping were helpful in identifying OSA and PLM in a well-screened sample of depressed insomniacs, PSG is required to definitively identify and exclude primary sleep disorders in insomnia clinical trials.


Subject(s)
Depressive Disorder/epidemiology , Sleep Wake Disorders/diagnosis , Sleep Wake Disorders/epidemiology , Actigraphy/statistics & numerical data , Adult , Age Distribution , Female , Humans , Male , Middle Aged , Polysomnography/statistics & numerical data , Predictive Value of Tests , Prevalence , ROC Curve , Sensitivity and Specificity , Sleep Initiation and Maintenance Disorders/epidemiology , Sleep Initiation and Maintenance Disorders/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...